Δ9-Tetrahydrocannabinol improves motor control in a patient with musician's dystonia [2]

Movement Disorders

Volumn 19, Issue 8, 2004, Pages 990-991

  Jabush, Hans Christian ^a   Schneider, Udo ^b   Altenmüller, Eckart ^a  

^a Hanover University of Music and Drama   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; DRONABINOL; PLACEBO; TRIHEXYPHENIDYL; PSYCHOTROPIC AGENT; TETRAHYDROCANNABINOL;

ADULT; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DYSTONIA; FATIGUE; FUNCTIONAL ASSESSMENT; HUMAN; LETTER; MALE; MENTAL CONCENTRATION; MENTAL DISEASE; MOTOR CONTROL; MOTOR PERFORMANCE; MUSICIAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; COMPARATIVE STUDY; DRUG EFFECT; MOTOR ACTIVITY; PATHOPHYSIOLOGY;

ADULT; DYSTONIC DISORDERS; HUMANS; MALE; MOTOR ACTIVITY; PSYCHOTROPIC DRUGS; TETRAHYDROCANNABINOL;

EID: 4444355930     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20214     Document Type: Letter

References (5)

1. Altenmüller E. Focal dystonia: advances in brain imaging and understanding of fine motor control in musicians. Hand Clin 2003; 19:523-538.
2. Richter A, Loscher W. (+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. Eur J Pharmacol 1994;264:371-377.
3. Fox SH, Kellett M, Moore AP. et al. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 2002;17:145-149.
4. Muller-Vahl KR, Prevedel H, Theloe K, et al. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no Influence on neuropsychological performance. Neuropsychopharmacology 2003;28:384-388.
5. Jabusch HC, Vauth H, Altenmüller E. Quantification of focal dystonia in pianists using scale analysis. Mov Disord 2004:19: 171-180.